April 7– Testimony Submitted to the Senate Finance Committee on drug pricing. Fran Visco, President, NBCC
June 29- Testimony Submitted to the House Ways and Means Subcommittee on Social Security Fran Visco, President, NBCC
June 25- Testimony Submitted to the House Appropriations Subcommittee on Defense Fran Visco, President, NBCC
April 14- Testimony Submitted to the Senate Appropriations Subcommittee on Defense Fran Visco, President, NBCC
April 8- Testimony Submitted to the House Appropriations Subcommittee on Defense Fran Visco, President, NBCC
March 21– House Ways and Means Subcommittee on Social Security Testimony on the Metastatic Breast Cancer Access to Care Act (MBCACA) Fran Visco, President, NBCC
NBCC’s advocacy has resulted in more than $4 billion federal dollars for breast cancer research.
NBCC has engaged as a key partner in seminal clinical trials, including the pivotal trial of trastuzumab (Herceptin)
Since 1995 NBCC has trained over 2,400 Project LEAD graduates in research and advocacy.
Through the Artemis Project®, NBCC developed a preventive vaccine that is now moving into a Phase I clinical trial.
